Clinical and radiographic response of extramedullary leukemia in patients treated with gemtuzumab ozogamicin

Michael J. McNeil*, Marguerite T. Parisi, Nobuko Hijiya, Soheil Meshinchi, Todd Cooper, Katherine Tarlock

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Extramedullary leukemia (EML) is common in pediatric acute leukemia and can present at diagnosis or relapse. CD33 is detected on the surface of myeloid blasts in many patients with acute myelogenous leukemia and is the target of the antibody drug conjugate gemtuzumab ozogamicin (GO). Here we present 2 patients with CD33+ EML treated with GO. They achieved significant response, with reduction of EML on both clinical and radiographic exams, specifically 18fluorine fluorodeoxyglucose positron emission tomography/computed tomography, demonstrating potential for targeted therapy with GO as a means of treating EML in patients with CD33+ leukemia and the utility of 18fluorine fluorodeoxyglucose positron emission tomography/computed tomography monitoring in EML.

Original languageEnglish (US)
Pages (from-to)E174-E176
JournalJournal of pediatric hematology/oncology
Volume41
Issue number3
DOIs
StatePublished - Apr 1 2019

Keywords

  • 18F-FDG PET/CT
  • Extramedullary leukemia
  • Gemtuzumab ozogamicin

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Clinical and radiographic response of extramedullary leukemia in patients treated with gemtuzumab ozogamicin'. Together they form a unique fingerprint.

Cite this